Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE

NCT06240143 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06240143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06240143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 8, 2024
Completion date
March 31, 2034
Enrollment
96 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma